LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Twist Bioscience Corp

Gesloten

SectorGezondheidszorg

46.65 -4.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

46.3

Max

48.93

Belangrijke statistieken

By Trading Economics

Inkomsten

-3.4M

-31M

Verkoop

4.7M

104M

Winstmarge

-29.419

Werknemers

979

EBITDA

-3.2M

-24M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+6.91% upside

Dividenden

By Dow Jones

Volgende Winsten

4 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

127M

2.7B

Vorige openingsprijs

50.9

Vorige sluitingsprijs

46.65

Nieuwssentiment

By Acuity

50%

50%

164 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Twist Bioscience Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mrt 2026, 23:36 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mrt 2026, 23:35 UTC

Acquisities, Fusies, Overnames

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mrt 2026, 23:29 UTC

Winsten

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mrt 2026, 23:27 UTC

Winsten

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mrt 2026, 23:27 UTC

Winsten

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mrt 2026, 23:08 UTC

Marktinformatie

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mrt 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mrt 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mrt 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Energy Roundup: Market Talk

26 mrt 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Peer Vergelijking

Prijswijziging

Twist Bioscience Corp Prognose

Koersdoel

By TipRanks

6.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52 USD  6.91%

Hoogste 58 USD

Laagste 50 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Twist Bioscience Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technische score

By Trading Central

31.56 / 38.6884Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

164 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat